Pepro Tech
Originally published online as doi:10.1189/JLB.1108713 on June 1, 2009

Published online before print June 1, 2009
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Buy
Right arrow All Versions of this Article:
JLB.1108713v1
86/3/625    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pan, P.
Right arrow Articles by Tsung, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pan, P.
Right arrow Articles by Tsung, A.
(Journal of Leukocyte Biology. 2009;86:625-632.)
© 2009 Society for Leukocyte Biology

Low-dose cisplatin administration in murine cecal ligation and puncture prevents the systemic release of HMGB1 and attenuates lethality

Pinhua Pan*,{dagger},1, Jon Cardinal*,1, Rajeev Dhupar*, Matthew R. Rosengart*, Michael T. Lotze*, David A. Geller*, Timothy R. Billiar* and Allan Tsung*,2

* Department of Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA; and
{dagger} Department of Pulmonary, Xiangya Hospital, Central South University, Changsha, China

2. Correspondence: University of Pittsburgh, Department of Surgery, 200 Lothrop St., Pittsburgh, PA 15213, USA. E-mail: tsunga{at}upmc.edu

ABSTRACT

Sepsis remains a major cause of morbidity and mortality worldwide. The systemic release of the nuclear protein HMGB1 is a late event in endotoxin-related lethality in mice. The platinating chemotherapeutic Cis induces DNA lesions that sequester HMGB1 within the nucleus of cells. We sought to determine if low, nontoxic doses of Cis could be an effective strategy in ameliorating sepsis-related mortality in a mouse model of CLP. In vitro studies with Cis prevented the LPS-induced release of HMGB1 from RAW264.7 cells, limited MAPK signaling, but had no effect on NF-{kappa}B activation or cytokine production. Low, nontoxic doses of Cis decreased mortality following CLP, whether delivered before or after puncture. Protection was associated with a decrease in the systemic release of HMGB1 and protection from end organ injury and in particular, less acute lung injury. Tissue-specific iNOS expression was markedly reduced. Low, nontoxic doses of Cis sequester HMGB1 effectively inside of the nucleus of LPS-stimulated immune cells and prevent its release in response to CLP. Platinating agents in general and Cis specifically may be a novel approach to the treatment of sepsis.

Key Words: platinum • sepsis • danger signaling • innate immunity • iNOS